We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases (SPINE2)

This study is currently recruiting participants.
Verified August 2016 by Institut de Recherche sur la Moelle épinière et l'Encéphale
Sponsor:
ClinicalTrials.gov Identifier:
NCT02885870
First Posted: September 1, 2016
Last Update Posted: September 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Nukleus
Information provided by (Responsible Party):
Institut de Recherche sur la Moelle épinière et l'Encéphale
  Purpose

The spinal cord is a common site for the development of several neurodegenerative neurological disorders (spinal muscular atrophy or SMA, amyotrophic lateral sclerosis or ALS, X-linked spinal bulbar muscular atrophy or SBMA). In different proportions, these diseases involve axonal loss in large funiculi of the spinal white matter, their demyelination, and loss of ventral horn motor neurons or motoneurones of the spinal gray matter. The lack of specific biomarkers of these macro and microscopic spinal damages, makes it difficult the differential diagnosis and monitoring of these diseases.

Techniques to explore non-invasively the human central nervous system, such as magnetic resonance imaging (MRI) and electrophysiology, are potential tools to extract specific biomarkers of spinal damages. However, imaging techniques are still poorly developed at spinal level for technical (specific antennas), anatomical (size of the spinal cord, vertebrae) and physiological reasons (cardio-respiratory movements). However, recent advances in the field of spinal cord imaging allowed to extract quantitative data on neuron loss, axonal degeneration and demyelination in different spinal pathologies whether degenerative (ALS or SMA) or traumatic (SCI). Correlations were found with clinical data, and in ALS patients, the changes in MRI metrics over time paralleled the functional deterioration. The electrophysiological techniques are used since a long time, leading to a good knowledge of the neurophysiology of human spinal cord. In addition, electrophysiology indirectly provides data at a microscopic scale, providing information on the excitability of spinal neural networks and giving an estimate of the amount of functional neurons.

By combining these techniques for the investigation of human spinal cord in vivo, the goal is to extract new biomarkers using as study models, diseases of the spinal cord affecting differentially the white and the gray matter (SMA, SBMA and ALS).

At first, new methods of diffusion MRI and modelling will be performed in healthy subjects to assess the axonal density and diameter of the fibers in the white matter. The anatomical imaging T2 will measure the geometrical parameters of the spinal cord such as its surface and/or volume at a given vertebral level. Thanks to imaging, we will construct via methods of segmentation and image processing, an atlas of the spinal cord that will allow to locate spatially spinal atrophy in patients. After this phase of validation, A study of patients will be conducted using these new MRI techniques, in addition to those already developed in the laboratory. The contribution of electrophysiology will be to assess more accurately the microscopic damage. Quantitative data from imaging and electrophysiology will be correlated with clinical data in order to extract the most relevant biomarkers.

This project has thus a methodological interest by proposing the development of new methods to assess the human spinal cord, at both macro and microscopic levels. These methods are based on the development of the techniques developed at spinal level and which are already applicable to human pathologies. The original combination of imaging and electrophysiology will also enable us to further analyze the human spinal cord, both anatomically and functionally. This project has an important clinical value for the extraction of biomarkers in diseases where there is an unmet need for diagnosis, monitoring, prognosis and evaluation of new therapies.


Condition Intervention
Spinal Cord Disease Procedure: Combination of multiparametric MRI and electrophysiology

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases

Resource links provided by NLM:


Further study details as provided by Institut de Recherche sur la Moelle épinière et l'Encéphale:

Primary Outcome Measures:
  • Change in MRI from baseline to follow-up visit [ Time Frame: Baseline, 6 months (amyotrophic lateral sclerosis patients) or 18 months (Spinal muscular atrophy and X-linked spinobulbar muscular atrophy patients) ]
    Assessment of the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration.


Estimated Enrollment: 105
Study Start Date: April 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patient

Patient with :

  • Spinal muscular atrophy (n=25)
  • X-linked spinobulbar muscular atrophy (n=25)
  • Amyotrophic lateral sclerosis (n=25)
Procedure: Combination of multiparametric MRI and electrophysiology
MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
Experimental: Healthy subject
Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
Procedure: Combination of multiparametric MRI and electrophysiology
MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

Spinal muscular atrophy patients :

  • Slowly progressive weakness related to pure lower motor neuron involvement X-linked spinobulbar muscular atrophy patients
  • Diagnosis confirmed by genetic testing (expansion of CAG trinucleotide repeats in the androgen receptor gene) Amyotrophic lateral sclerosis patients
  • ALS definite or probable according to El Escorial criteria - No bulbar or breathing impairment preventing decubitus

Healthy volunteers

- Subjects without any neurologic or spine affection - Subjects matched for sex and age

Exclusion criteria

  • Subjects not able to understand the investigator
  • Subjects who are not affiliated to the national health insurance fund
  • Contraindications to resonance imaging
  • Contraindication to transcranial magnetic stimulation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02885870


Contacts
Contact: sophie BLANCHO +33 6 07 16 04 05 irme@noos.fr

Locations
France
BLANCHO Recruiting
Paris, France, 75015
Contact: SOPHIE BLANCHO    +33 6 07 16 04 05    IRME@noos.fr   
Principal Investigator: Pierre-Francois PRADAT         
Sponsors and Collaborators
Institut de Recherche sur la Moelle épinière et l'Encéphale
Nukleus
  More Information

Responsible Party: Institut de Recherche sur la Moelle épinière et l'Encéphale
ClinicalTrials.gov Identifier: NCT02885870     History of Changes
Other Study ID Numbers: 2015-A01164-45
First Submitted: August 22, 2016
First Posted: September 1, 2016
Last Update Posted: September 1, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Institut de Recherche sur la Moelle épinière et l'Encéphale:
biomarker
spinal cord disease
resonance imaging
electrophysiology

Additional relevant MeSH terms:
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases